Related Experiment Video
Updated: Aug 10, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma
Takafumi Yanagisawa1, Manuela Schmidinger2, Tatsushi Kawada3
1Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Abstract:
Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. PATIENT SUMMARY: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.
More Related Videos
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention

